Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle: e0140471

Background 30 years ago, the potential of bispecific antibodies to engage cytotoxic T cells for the lysis of cancer cells was discovered. Today a variety of bispecific antibodies against diverse cell surface structures have been developed, the majority of them produced in mammalian cell culture syst...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2015-01, Vol.10 (10)
Hauptverfasser: Spiesberger, Katrin, Paulfranz, Florian, Egger, Anton, Reiser, Judith, Vogl, Claus, Rudolf-Scholik, Judith, Mayrhofer, Corina, Grosse-Hovest, Ludger, Brem, Gottfried
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 10
container_start_page
container_title PloS one
container_volume 10
creator Spiesberger, Katrin
Paulfranz, Florian
Egger, Anton
Reiser, Judith
Vogl, Claus
Rudolf-Scholik, Judith
Mayrhofer, Corina
Grosse-Hovest, Ludger
Brem, Gottfried
description Background 30 years ago, the potential of bispecific antibodies to engage cytotoxic T cells for the lysis of cancer cells was discovered. Today a variety of bispecific antibodies against diverse cell surface structures have been developed, the majority of them produced in mammalian cell culture systems. Beside the r28M, described here, no such bispecific antibody is known to be expressed by transgenic livestock, although various biologicals for medical needs are already harvested-mostly from the milk-of these transgenics. In this study we investigated the large-scale purification and biological activity of the bispecific antibody r28M, expressed in the blood of transgenic cattle. This tandem single-chain variable fragment antibody is designed to target human CD28 and the melanoma/glioblastoma-associated cell surface chondroitin sulfate proteoglycan 4 (CSPG4). Results With the described optimized purification protocol an average yield of 30 mg enriched r28M fraction out of 2 liters bovine plasma could be obtained. Separation of this enriched fraction by size exclusion chromatography into monomers, dimers and aggregates and further testing regarding the biological activity revealed the monomer fraction as being the most appropriate one to continue working with. The detailed characterization of the antibody's activity confirmed its high specificity to induce the killing of CSPG4 positive cells. In addition, first insights into tumor cell death pathways mediated by r28M-activated peripheral blood mononuclear cells were gained. In consideration of possible applications in vivo we also tested the effect of the addition of different excipients to r28M. Conclusion Summing up, we managed to purify monomeric r28M from bovine plasma in a large-scale preparation and could prove that its biological activity is unaffected and still highly specific and thus, might be applicable for the treatment of melanoma.
doi_str_mv 10.1371/journal.pone.0140471
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1732820795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1732820795</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_17328207953</originalsourceid><addsrcrecordid>eNqVjr1uwjAUha1KlaA_b9Dhjl2S2jEkgY2iIoYiITU7ujg3kZFjp_6p1KHvXpB4AaYzfOc7Ooy9CJ4LWYm3k0veoslHZynnYsZnlbhjU7GQRVYWXE7YQwgnzueyLssp-_tE31P2pdAQ7JPXnVYYtbPgOvBFvVvCCt51GEldEAS1-YGVjfro2l9oLnLUtodtGtDCjgxaNyDsvWuToha0hcajDT3Zs73GGA0tga7Hnth9hybQ8zUf2evmo1lvs9G770QhHgYdFJnzKrkUDqKSRV3wajGXN1T_AaOgWC8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1732820795</pqid></control><display><type>article</type><title>Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle: e0140471</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Spiesberger, Katrin ; Paulfranz, Florian ; Egger, Anton ; Reiser, Judith ; Vogl, Claus ; Rudolf-Scholik, Judith ; Mayrhofer, Corina ; Grosse-Hovest, Ludger ; Brem, Gottfried</creator><creatorcontrib>Spiesberger, Katrin ; Paulfranz, Florian ; Egger, Anton ; Reiser, Judith ; Vogl, Claus ; Rudolf-Scholik, Judith ; Mayrhofer, Corina ; Grosse-Hovest, Ludger ; Brem, Gottfried</creatorcontrib><description>Background 30 years ago, the potential of bispecific antibodies to engage cytotoxic T cells for the lysis of cancer cells was discovered. Today a variety of bispecific antibodies against diverse cell surface structures have been developed, the majority of them produced in mammalian cell culture systems. Beside the r28M, described here, no such bispecific antibody is known to be expressed by transgenic livestock, although various biologicals for medical needs are already harvested-mostly from the milk-of these transgenics. In this study we investigated the large-scale purification and biological activity of the bispecific antibody r28M, expressed in the blood of transgenic cattle. This tandem single-chain variable fragment antibody is designed to target human CD28 and the melanoma/glioblastoma-associated cell surface chondroitin sulfate proteoglycan 4 (CSPG4). Results With the described optimized purification protocol an average yield of 30 mg enriched r28M fraction out of 2 liters bovine plasma could be obtained. Separation of this enriched fraction by size exclusion chromatography into monomers, dimers and aggregates and further testing regarding the biological activity revealed the monomer fraction as being the most appropriate one to continue working with. The detailed characterization of the antibody's activity confirmed its high specificity to induce the killing of CSPG4 positive cells. In addition, first insights into tumor cell death pathways mediated by r28M-activated peripheral blood mononuclear cells were gained. In consideration of possible applications in vivo we also tested the effect of the addition of different excipients to r28M. Conclusion Summing up, we managed to purify monomeric r28M from bovine plasma in a large-scale preparation and could prove that its biological activity is unaffected and still highly specific and thus, might be applicable for the treatment of melanoma.</description><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0140471</identifier><language>eng</language><ispartof>PloS one, 2015-01, Vol.10 (10)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27905,27906</link.rule.ids></links><search><creatorcontrib>Spiesberger, Katrin</creatorcontrib><creatorcontrib>Paulfranz, Florian</creatorcontrib><creatorcontrib>Egger, Anton</creatorcontrib><creatorcontrib>Reiser, Judith</creatorcontrib><creatorcontrib>Vogl, Claus</creatorcontrib><creatorcontrib>Rudolf-Scholik, Judith</creatorcontrib><creatorcontrib>Mayrhofer, Corina</creatorcontrib><creatorcontrib>Grosse-Hovest, Ludger</creatorcontrib><creatorcontrib>Brem, Gottfried</creatorcontrib><title>Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle: e0140471</title><title>PloS one</title><description>Background 30 years ago, the potential of bispecific antibodies to engage cytotoxic T cells for the lysis of cancer cells was discovered. Today a variety of bispecific antibodies against diverse cell surface structures have been developed, the majority of them produced in mammalian cell culture systems. Beside the r28M, described here, no such bispecific antibody is known to be expressed by transgenic livestock, although various biologicals for medical needs are already harvested-mostly from the milk-of these transgenics. In this study we investigated the large-scale purification and biological activity of the bispecific antibody r28M, expressed in the blood of transgenic cattle. This tandem single-chain variable fragment antibody is designed to target human CD28 and the melanoma/glioblastoma-associated cell surface chondroitin sulfate proteoglycan 4 (CSPG4). Results With the described optimized purification protocol an average yield of 30 mg enriched r28M fraction out of 2 liters bovine plasma could be obtained. Separation of this enriched fraction by size exclusion chromatography into monomers, dimers and aggregates and further testing regarding the biological activity revealed the monomer fraction as being the most appropriate one to continue working with. The detailed characterization of the antibody's activity confirmed its high specificity to induce the killing of CSPG4 positive cells. In addition, first insights into tumor cell death pathways mediated by r28M-activated peripheral blood mononuclear cells were gained. In consideration of possible applications in vivo we also tested the effect of the addition of different excipients to r28M. Conclusion Summing up, we managed to purify monomeric r28M from bovine plasma in a large-scale preparation and could prove that its biological activity is unaffected and still highly specific and thus, might be applicable for the treatment of melanoma.</description><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqVjr1uwjAUha1KlaA_b9Dhjl2S2jEkgY2iIoYiITU7ujg3kZFjp_6p1KHvXpB4AaYzfOc7Ooy9CJ4LWYm3k0veoslHZynnYsZnlbhjU7GQRVYWXE7YQwgnzueyLssp-_tE31P2pdAQ7JPXnVYYtbPgOvBFvVvCCt51GEldEAS1-YGVjfro2l9oLnLUtodtGtDCjgxaNyDsvWuToha0hcajDT3Zs73GGA0tga7Hnth9hybQ8zUf2evmo1lvs9G770QhHgYdFJnzKrkUDqKSRV3wajGXN1T_AaOgWC8</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Spiesberger, Katrin</creator><creator>Paulfranz, Florian</creator><creator>Egger, Anton</creator><creator>Reiser, Judith</creator><creator>Vogl, Claus</creator><creator>Rudolf-Scholik, Judith</creator><creator>Mayrhofer, Corina</creator><creator>Grosse-Hovest, Ludger</creator><creator>Brem, Gottfried</creator><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20150101</creationdate><title>Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle: e0140471</title><author>Spiesberger, Katrin ; Paulfranz, Florian ; Egger, Anton ; Reiser, Judith ; Vogl, Claus ; Rudolf-Scholik, Judith ; Mayrhofer, Corina ; Grosse-Hovest, Ludger ; Brem, Gottfried</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_17328207953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spiesberger, Katrin</creatorcontrib><creatorcontrib>Paulfranz, Florian</creatorcontrib><creatorcontrib>Egger, Anton</creatorcontrib><creatorcontrib>Reiser, Judith</creatorcontrib><creatorcontrib>Vogl, Claus</creatorcontrib><creatorcontrib>Rudolf-Scholik, Judith</creatorcontrib><creatorcontrib>Mayrhofer, Corina</creatorcontrib><creatorcontrib>Grosse-Hovest, Ludger</creatorcontrib><creatorcontrib>Brem, Gottfried</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spiesberger, Katrin</au><au>Paulfranz, Florian</au><au>Egger, Anton</au><au>Reiser, Judith</au><au>Vogl, Claus</au><au>Rudolf-Scholik, Judith</au><au>Mayrhofer, Corina</au><au>Grosse-Hovest, Ludger</au><au>Brem, Gottfried</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle: e0140471</atitle><jtitle>PloS one</jtitle><date>2015-01-01</date><risdate>2015</risdate><volume>10</volume><issue>10</issue><eissn>1932-6203</eissn><abstract>Background 30 years ago, the potential of bispecific antibodies to engage cytotoxic T cells for the lysis of cancer cells was discovered. Today a variety of bispecific antibodies against diverse cell surface structures have been developed, the majority of them produced in mammalian cell culture systems. Beside the r28M, described here, no such bispecific antibody is known to be expressed by transgenic livestock, although various biologicals for medical needs are already harvested-mostly from the milk-of these transgenics. In this study we investigated the large-scale purification and biological activity of the bispecific antibody r28M, expressed in the blood of transgenic cattle. This tandem single-chain variable fragment antibody is designed to target human CD28 and the melanoma/glioblastoma-associated cell surface chondroitin sulfate proteoglycan 4 (CSPG4). Results With the described optimized purification protocol an average yield of 30 mg enriched r28M fraction out of 2 liters bovine plasma could be obtained. Separation of this enriched fraction by size exclusion chromatography into monomers, dimers and aggregates and further testing regarding the biological activity revealed the monomer fraction as being the most appropriate one to continue working with. The detailed characterization of the antibody's activity confirmed its high specificity to induce the killing of CSPG4 positive cells. In addition, first insights into tumor cell death pathways mediated by r28M-activated peripheral blood mononuclear cells were gained. In consideration of possible applications in vivo we also tested the effect of the addition of different excipients to r28M. Conclusion Summing up, we managed to purify monomeric r28M from bovine plasma in a large-scale preparation and could prove that its biological activity is unaffected and still highly specific and thus, might be applicable for the treatment of melanoma.</abstract><doi>10.1371/journal.pone.0140471</doi></addata></record>
fulltext fulltext
identifier EISSN: 1932-6203
ispartof PloS one, 2015-01, Vol.10 (10)
issn 1932-6203
language eng
recordid cdi_proquest_miscellaneous_1732820795
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry
title Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle: e0140471
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T05%3A37%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Large-Scale%20Purification%20of%20r28M:%20A%20Bispecific%20scFv%20Antibody%20Targeting%20Human%20Melanoma%20Produced%20in%20Transgenic%20Cattle:%20e0140471&rft.jtitle=PloS%20one&rft.au=Spiesberger,%20Katrin&rft.date=2015-01-01&rft.volume=10&rft.issue=10&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0140471&rft_dat=%3Cproquest%3E1732820795%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1732820795&rft_id=info:pmid/&rfr_iscdi=true